Search form

Latest News

Quidel Receives 510(k) Clearance for QuickVue® Influenza A+B Test, Assay Meets FDA’s Class II RIDT Requirements

SAN DIEGO--(BUSINESS WIRE)--Feb. 13, 2018--
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic
testing solutions, cellular-based virology assays and molecular
diagnostic systems, announced today that it has received 510(k)
clearance from the United States Food and Drug Administration (FDA) for
Quidel’s CLIA Waived QuickVue® Influenza A+B assay for the rapid,
differential detection of influenza types A and B.

Read More »

Careers

Are you a determined, optimistic, team player? Quidel is looking for talented innovators who want to be part of revolutionizing medical diagnostics.

View Current Job Openings

Support

To place orders, get assistance with shipments, pricing or contract administration view our Customer Support page.

Visit our Technical Support page to get help with product specifications, supporting docs or general support issues.

NEW: Register at MyQuidel.com to download and install the latest Software Updates, Assay and testing capabilities for your Quidel Instruments.